Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of DF19001 in House Dust Mite Allergic Rhinitis
NCT05525650Phase 1Enrolling by invitation
- Sponsor
- Raphas
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DF19001 in allergic rhinitis (AR) (6 arms), sponsored by Raphas. Primary endpoints: Vital signs, Health examination and 4 more. Started Jan 2022; status: enrolling by invitation.
02
Drugs
DF19001
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05525650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525650.